AVI BioPharma shares could rise: Barron’s

(Reuters) – Shares in biotechnology company AVI BioPharma (AVII.O) could rise significantly in the next 12 months if it continues to report favorable results from trials of its drugs, Barron’s reported on Sunday.

Hot Stocks

AVI BioPharma is working on treatments for high-profile diseases such as swine flu, according to Barron’s.

The company earlier this month reported positive results from a study of a drug it designed to treat a genetic muscle-wasting disease.

But AVI shares have seen little recognition from Wall Street, in part because the company has no drugs on the market, it is in the early stages of testing its treatments and it has little revenue outside of government grants, the newspaper reported.

The company is seeking a large investment partner that could help finance its drug development and help validate the company, Barron’s said. If it is able to do such a deal, AVI shares could jump significantly, the newspaper said.

AVI shares closed at $1.45 on Friday. The shares were at $1.46 at the end of 2009.

(Reporting by Elinor Comlay; Editing by Diane Craft)

Experts find compound to fight bird, seasonal flu

(Reuters) – Scientists have identified a chemical compound that can stop the H5N1 bird flu virus as well as seasonal human flu viruses from replicating.

Health

Finding new flu drugs is essential as flu viruses mutate and are adept at evading the limited array of antiviral drugs.

In a paper published in Nature Biotechnology, scientists from Hong Kong and Canada said they had found a chemical “nucleozin,” which fought off both seasonal flu viruses and the H5N1 in mice as well as in cell culture.

“We have now brand-new weapons to combat influenza virus resistant to … (antiviral drugs like) oseltamivir and zanamivir,” said microbiologist Richard Yao at the University of Hong Kong, who led the study.

Nearly all of the seasonal H1N1 viruses circulating in the United States in the 2008-2009 flu season were resistant to Roche AG and Gilead Sciences Inc’s Tamiflu, known generically as oseltamivir, according to the paper.

Adamantanes, an older class of drugs, was also powerless against seasonal H3N2 flu viruses in the United States during that same period.

Zanamivir is the generic name for Relenza, GlaxoSmithKline and Biota Inc’s flu drug

Nucleozin targeted a protein in flu viruses, called nucleoprotein, that was responsible for virus replication, Yao said in reply to questions from Reuters.

Yao said they selected nucleozin from a chemical library with more than 50,000 compounds, the same library which experts here used to study the SARS virus.

“Nucleozin is highly potent in cell culture and also in mice infected with the highly pathogenic influenza virus H5N1 … (it can) stop the virus from replicating,” Yao said.

The compound was effective against H1N1, H3N2, and H5N1 viruses and researchers can now target nucleoprotein to fight flu, Yao said.

“Scientists could now use nucleoprotein as a target to develop antiviral therapeutics for the treatment of influenza infection,” he said.

A cousin of the new H1N1 swine flu virus, the seasonal H1N1, has been circulating widely for a long time. SARS surfaced in southern China in 2003, killing about 800 people world-wide.

The H5N1, although mainly a disease in birds, has a mortality rate of 60 percent on the rare occasions when it infects people. It was first discovered in people in 1997.

(Reporting by Tan Ee Lyn; Editing by Ron Popeski)

Seaweed may halt swine flu spread

Tasmanian scientists have discovered a compound occuring naturally in seaweed which could help provide the key to beating swine flu.

The Japanese seaweed Undaria arrived in Tasmania in ballast water more than 20 years ago.

A compound in the seaweed acts as a natural defence against marine viruses and toxins.

Scientists at a private laboratory near Hobart are convinced it is just as effective on humans.

They have tested the compound against several viruses and say it profoundly inhibits the H1N1 virus.

Researcher Dr Helen Fitton says viruses use receptors to get into cells, but this process is stopped in the presence of the seaweed compound.

“The virus is unable to use its receptor to get into the cell,” she said.

Marinova Laboratories CEO Paul Garrott says he is anticipating immediate commercial interest and expects the compound will be used in nasal sprays, hand washes and tablets.

“This whole class of fucoidan compounds have been shown to have very profound antiviral activities against a range of influenza strains, against a range of other viruses and coated viruses – we mentioned HIV, we mentioned the herpes simplex virus.”

Six anti-govt protesters in Bangkok have swine flu: hospital

Bangkok, April 26 — Six guards of the anti-government protesters camped in central Bangkok have caught the deadly H1N1 swine flu virus, a public hospital chief said. Laboratory tests on Saturday confirmed the six young men, ranging in age from 16 to 42 years, have the virus, the chief said yesterday. “They have been sleeping in a group of some 50 people and they could easily spread the virus,” Pichaya Nakawachara, head of Bangkok’s General Hospital, warned. Seven guards went to the hospital last week with flu-like symptoms, but none of them are in serious condition. They were merely given medication, the doctor said. Six of them remain in hospital.

Recently, 10,000-20,000 protesters gather at the rally site during peak hours in the evening, but the numbers drop early in the morning.

1976 swine flu immunization might protect against pandemic H1N1 virus

Washington, April 24 (ANI): A new American study has linked 1976 ”swine flu” shot to stronger immune response to 21st century pandemic flu.

Researchers at St. Jude Children”s Research Hospital found that individuals who reported receiving the 1976 vaccine mounted an enhanced immune response against both the 2009 pandemic H1N1 virus and a different H1N1 flu strain that circulated during the 2008-09 flu season.

Lead author Jonathan A. McCullers, an associate member of the St. Jude Infectious Diseases Department, said: “Our research shows that while immunity among those vaccinated in 1976 has waned somewhat, they mounted a much stronger immune response against the current pandemic H1N1 strain than others who did not receive the 1976 vaccine.”

McCullers said it is unclear if the response was enough to protect against the 2009 H1N1 virus, but the study points to a lingering benefit.

The findings also raise hope that those vaccinated against the 2009 H1N1 pandemic strain might also enjoy a similar long-term advantage.

The study is the first to focus on whether those vaccinated against the 1976 H1N1 strain made antibodies against the 2009 pandemic flu, including antibodies that could block the virus from infecting cells.

The study involved 116 St. Jude employees and spouses age 55 and older.

The group included 46 vaccinated in 1976 against the H1N1 flu virus, known as A/New Jersey/76, which sickened more than 200 military recruits in New Jersey.

That outbreak triggered fears of a flu pandemic and led to a massive government effort to quickly produce and distribute a vaccine.

The current study was conducted in August 2009 before a vaccine was available against the pandemic H1N1 flu strain and before the virus was circulating widely in the Memphis, Tenn., metropolitan area, where study volunteers lived.

Researchers reported that nearly 90 percent of volunteers made antibodies able to recognize a key protein on the surface of both the 2009 pandemic and the 2008-09 H1N1 flu strains.

Those antibodies were present in numbers large enough to meet one federal gauge of vaccine effectiveness.

Nineteen percent of volunteers also produced antibodies that neutralized the 2009 pandemic strain and blocked it from infecting cells.

In comparison, more than 67 percent of volunteers had antibodies that neutralized the 2008-09 seasonal H1N1 strain.

Those vaccinated in 1976 were more likely to make neutralizing antibodies against the new pandemic strain.

More than 17 percent of the 1976-vaccine group made such antibodies in large quantities.

Only about 4 percent of those who had not received the 1976 shot had comparable levels of antibody production.

The difference between the two groups was statistically significant, meaning it was unlikely chance alone explained the result.

The study has been published in the online issue of the journal Clinical Infectious Diseases. (ANI)

Now, painless vaccines!

it surely was too much pain, for a lot of good. Now, the trade-off is unlikely to stay current.

In what would make childhood immunisation easier and pain-free, scientists have developed a patch — the size of a postage stamp — which they claim could be used to deliver cheap, needle-free vaccines.

A new study, led by the University of Queensland, has found that a vaccine delivered by ‘Nanopatch’ induces a similarly protective immune response as a vaccine delivered by needle and syringe, but uses 100 times less vaccine.

According to the scientists, the patch could be used in developing countries where clean needles and refrigeration are scarce.

“The Nanopatch targeted specific antigen presenting cells found in a narrow layer just beneath the skin surface and as a result we used less than one hundredth of dose used by a needle while stimulating a comparable immune response.

“Our result is ten times better than the best results achieved by other delivery methods and does not require the use of other immune stimulants, called adjuvants, or multiple vaccinations.

“Because the Nanopatch requires neither a trained practitioner to administer it nor refrigeration, it has enormous potential cheaply deliver vaccines in developing nations,” lead scientist Professor Mark Kendall said.

According to the scientists, the Nanopatch comprises of several thousands of densely packed projections invisible to the human eye. The influenza vaccine was dry coated onto the projections and applied to skin of mice for two minutes.

“By using far less vaccine we believe that the Nanopatch will enable the vaccination of many more people.

When compared to a needle and syringe a Nanopatch is cheap to produce and it is easy to imagine a situation in which a government might provide vaccinations for a pandemic such as swine flu to be collected from a chemist or sent in the mail.

“This is an exciting discovery and our next step s to prove the effectiveness of Nanopatches in human clinical rials,” Professor Kendall said.

Pandemic remains threat to young, top expert warns

GENEVA, April 14 (Reuters) – The H1N1 flu pandemic is as severe as influenza pandemics in 1957 and 1968 and remains a threat, especially to healthy young adults, the chairman of the WHO’s Emergency Committee said on Wednesday.

John Mackenzie, the Australian expert who heads the independent but secretive advisory body, also said that he was not aware of any of its 15 members being approached by drug companies seeking to influence their decision-making.

“This is just as severe as we saw in 1957 and 1968, with one major difference. We are not seeing deaths in the elderly but we are seeing them in a more important group of the population, healthy young adults,” Mackenzie said in a rare presentation.

“It is much more severe than people tend to talk about,” he told a three-day meeting called to review the way the World Health Organisation (WHO) handled the pandemic.

The official death toll so far from H1N1 is 17,700, but WHO says it will take at least a year or two after the pandemic ends to establish the true number.

The 1957 and 1968 pandemics killed around 2 million and 1 million respectively, according to the WHO. Seasonal flu kills up to 500,000 a year, 90 percent of them frail elderly people.

The Emergency Committee played a key role in advising the United Nations agency on progressively moving up its six-phase scale, leading to declaration of a full pandemic last June.

Phase changes have implications for switching from production of seasonal flu vaccine to pandemic vaccine. Moving to phase 6 also triggered advance purchase agreements that some Western countries had with drug companies.

Swine flu has turned out to be less severe than feared, and critics have said the WHO created needless panic and caused Western governments to stockpile vaccines that went unused.

Mackenzie said he expected the committee to convene again in two or three weeks to advise WHO director-general Margaret Chan on whether the world has moved to a post-peak phase. But he indicated that such a decision remained premature.

“STILL IN A PANDEMIC”

“We still have evidence of the pandemic in Asia and in West Africa,” he said. “We also want to see what happens in a second wave in the southern hemisphere. We have no idea what will happen and have some concerns.

“I would say, yes, we are still in a pandemic phase 6 … We cannot lower our guard.”

Mackenzie said the committee had taken unanimous decisions on difficult issues based on what evidence was available.

“I as chairman was not approached at any stage by the pharmaceutical industry. I don’t know of any member being approached and I would very much doubt it,” he said.

“We did not want to see production of seasonal vaccine discontinued if the pandemic was going to disappear.”

No Emergency Committee members apart from Mackenzie are identified publicly — a policy intended to protect them from commercial or political influence.

David Salisbury, head of the WHO’s vaccine advisory body, the Scientific Advisory Group for Emergencies (SAGE), said it had become clear only last October that a single dose of vaccine would be sufficient to provide immunity for adults, and not two as generally expected.

He also denied that SAGE’s members had been coerced:

“No attempt was made at any time to influence the advice we gave either in terms of the time we gave it or the content. To my knowledge, the industry has done nothing to us other than provide scientific information.”

GlaxoSmithKline (GSK.L) and Sanofi-Aventis (SASY.PA) are among firms that have raced to produce H1N1 vaccines. (Editing by Jonathan Lynn and Kevin Liffey)

Mass vaccinations an overreaction to flu epidemic

A leading health expert has called for a rethink on mass immunisations against influenza.

Professor Peter Collignon, an expert in infectious diseases from the Australian National University, says the handling of the swine flu response last year is an example of how not to handle an outbreak.

He says the swine flu response last year need not have included mass vaccinations or pandemic plans as the mortality rate was quite low.

He says mass vaccination programs often mean people who do not really need the drugs get them before people in more dire need.

“Because there was a general panic in society, the wrong people got the drugs at the wrong time,” he said.

“We ran the risk of paralysing our health system with people, 99 per cent of whom would have got better by themselves anyway by just being at home, taking fluids, taking panadol … and keeping away from people so they didn’t spread the infection.”

Professor Collignon says attempting to vaccinate everyone, as happened with the swine flu outbreak in Australia last year, overwhelms the health system.

“We don’t want to necessarily immunise the whole population with a vaccine,” he said.

“We want to target our response to those who are at risk and I think we need to learn from this so that we do this better in the future.

“This has been a problem where there’s been resources allocated for swine flu which probably could have been better, in retrospect, allocated elsewhere.”

Swine flu jab countdown

Tasmanians are again being urged to vaccinate themselves against swine flu this winter.

Health authorities predict that swine flu will be the state’s leading form of influenza for 2010.

Graeme Lynch from the Tasmanian Chronic Disease Prevention Alliance says 50 cases of swine flu have already been reported in the country this year.

“It’s really important for people who are at risk with their health, and particularly those people who suffer from chronic disease, to make sure that they are immunised against swine flu and against influenza generally,” he said.

“It’s not about treating people with ill health. It’s about protecting people’s health so our mission is to promote good health, good living and part of that is to take necessary precautions against things like influenza.”

Free vaccinations are being offered to all Tasmanians over the age of six months.

ANA upbeat on recovery in travel demand

(Reuters) – All Nippon Airways Co, headed for a $693 million loss in the just-ended financial year, said its profitability has started to bounce back thanks to a recovery in travel demand, particularly in the high-margin business class segment.

Hot Stocks

The airline, Japan’s second-biggest by revenue, is also considering starting a low-cost carrier, its president said, eyeing growing demand among budget travelers.

ANA, like other global airlines, was smacked down last year by a sputtering economy and outbreak of H1N1 swine flu that led to the industry’s sharpest decline in passenger traffic in decades and sent Japan Airlines (JAL) into bankruptcy.

But thanks to a recovery in passenger demand in the past few months, ANA is seeing more than 40 percent growth in business passenger bookings for May compared with a year earlier and higher sales.

“Passenger bookings are showing double-digit growth for international operations for April and also May,” ANA president Shinichiro Ito told Reuters in an interview on Friday.

“A stabilized economy is seen creating more business travel demand. Some (passenger) inflow from JAL is also seen,” he said.

ANA, the third-biggest airline by market capital in Asia after Air China Ltd and Singapore Airlines, surprised investors last month when it forecast a bigger net loss for the year ended March 31 after the weak global economy and swine flu hit its revenues.

To return to profit in the year that started April 1, ANA is stepping up cost-cutting measures including slashing 1,000 jobs.

“The year 2010 is strategically important for us. We aim to return to profit, Boeing Co’s 787 delivery is scheduled and the expansion for Haneda airport is planned,” said Ito.

The industry association IATA said last month that airlines are recovering strongly from the crisis, as passengers, freight and pricing power return, though the industry is still deeply in the red.

LOW-COST CARRIER

ANA, a launch customer of Boeing’s 787 Dreamliner, has been eyeing a global expansion to strengthen its ties with Star Alliance partner carriers such as United Airlines and Lufthansa.

It aims to boost its international travel revenues by 68 percent to 357 billion yen in the year ending March 2012 from the year just ended.

ANA is also “seriously considering” the possibility of starting a low-cost carrier (LCC), said Ito, who says he is too busy managing the airline to go fishing — his favorite hobby.

“But we would first need to see whether the LCC model would really work in Japan. To operate an LCC, we’ll also need find airports that are open 24-hours-a-day with low landing fees,” he said.

LCCs have been on the increase throughout the world, but Japan has always been a difficult market due to high labor costs, limited slot availability at key airports and expensive landing fees.

Shares of ANA have gained 6.7 percent since the start of the year, in line with the rise in the benchmark Nikkei average.

($1=93.76 Yen)

(Editing by Chris Gallagher)

Nip and tuck for emergency wait times

The latest quarterly report on the ACT’s public health system shows the Government is making some headway reducing emergency waiting times but it is still a long way off national benchmarks.

ACT public hospitals saw just under 61 per cent of less urgent emergency patients on time in the second half of last year.

That is a substantial improvement on the same period last year when only 47 per cent were seen on time.

But it is still well below the national benchmark of 75 per cent.

The proportion of emergency patients being treated who have to wait more than eight hours before being transferred to a bed increased slightly from 28 to 29 per cent.

The report also found 9 per cent of elective surgery cases were postponed in the second half of last year.

It says that was because swine flu cases put extra pressure on hospitals.

Health Minister Katy Gallagher says the report shows signs of consistent improvement.

“We’re not going to see dramatic improvements within a quarter but we’re seeing consistent gradual improvement,” she said.

“I hope the new beds and the new ways of doing things will continue to build on it.”

But Opposition health spokesman Jeremy Hanson says it is proof the health system is still in trouble.

He says the Government has gone backwards in areas like elective surgery.

“We’re still stuck in a rut at the bottom of the pile when it comes to health outcomes here in the ACT in particular in relation to access to services,” he said.

“There are some marginal improvements in some areas and some declines in others but broadly speaking I think it’s a status quo support.”

Structure of ”swine flu” virus found

Washington, Mar 25 (ANI): The structure of a key protein from the virus that caused last year”s “swine flu” influenza epidemic has been solved by a team of scientists from The Scripps Research Institute and other institutions.

The development explain why young people have been more vulnerable than older individuals in recent pandemic.

The structure reveals that the virus shares many features with influenza viruses common in the early 20th century.

The team”s findings were published in the March 25, 2010, issue of Science Express, an advance, online publication of selected research papers from the prestigious journal Science.

In the study, the team describes the structure of the hemagglutinin (the influenza virus envelope protein) from the H1N1 swine flu virus that triggered the pandemic in 2009 and is still circulating in the human population. The team then compared the swine flu hemagglutinin protein with a range of different human H1N1 flu viruses in the past century.

“Parts of the 2009 virus are remarkably similar to human H1N1 viruses circulating in the early 20th century,” said Scripps Research Professor Ian Wilson, who was the senior author of the study. “Our findings provide strong evidence that exposure to earlier viruses has helped to provide some people with immunity to the recent influenza pandemic.”

The information should be useful for scientists and public health officials as they respond to current and future pandemics. (ANI)

Women with swine flu more likely to suffer critical illness if pregnant

London, Mar 19 (ANI): Pregnant women with swine flu are 13 times more likely to become critically ill than non-pregnant women infected with H1N1, concludes a new study.

The research, published on bmj.com, included pregnant women in Australia and New Zealand.

Boffins concluded that 11 percent of mothers and 12 percent of babies died as a result of being admitted to intensive care with swine flu.

The authors, led by Dr Ian Seppelt from the Australian and New Zealand Intensive Care (ANZIC) Influenza Investigators in collaboration with the Australasian Maternity Outcomes Surveillance System, assessed the data relating to all women with swine flu who were pregnant or who had given birth in the last 28 days and were admitted to an ICU in Australia or New Zealand between 1 June and 31 August 2009.

The results show that women who were more than 20 weeks pregnant were 13 times more likely to be admitted to an ICU than non-pregnant women who had swine flu. (ANI)

Downpour deterring tourists

Tourism Sunshine Coast says the persistent wet weather is keeping tourists away.

Chief executive Russell Mason says some operators have reported bookings are down 15 to 20 per cent on this time last year when there was a swine flu outbreak, the global financial crisis and a cyclone.

He says Easter bookings are not very strong because people are waiting to see whether the rain will continue.

“The industry puts money aside for a rainy day but when you have a rainy month or a rainy two months it does start to become quite an issue,” he said.

“Easter is the last real period that we hope to get good bookings between now and the end of the financial year, so it’s a crucial period for the industry.”

Lohan sparks swine flu fears with “achey” tweet

London, Mar 16 (ANI): Lindsay Lohan is said to have sparked fears she has contracted swine flu after she asked followers on Twitter.com about the symptoms of the illness, and adding that she was feeling “achey”.

Lohan, 23, posted a note on her page asking fans, “What are the symptoms of Swine Flu?” and then added she was worried she had the virus as one of her pals had fallen ill with it.

“Achey? My friend had it and I am sick and I’m now concerned!!!!” the Daily Star quoted her as having written.

Concerned fans immediately sent her a barrage of messages, and she in turn had to tell them that she did not say she had the virus and that she was going to the doctor for a check-up just in case.

“I never said I have it or anything, I was just reaching out to ask because everyone here may know different things about it,” she said.

Adding: “Isn’t this what Twitter is for? I don’t (know if I have it) and my doctor is coming now. I didn’t Google it b/c (because) this seemed more convenient.” (ANI)

BCCI secretary N. Srinivasan, Dhoni Banned, Dhoni banned for 2 ODI, Dhoni banned for 2 ODI’s for slow over rate, Dhoni banned for 2 One Day Matches, Dinesh Karthik, Dinesh Karthik to replace MS Dhoni, Ishant Sharma, Jeff Crowe, M. S Dhoni Banned, Mahendra S Dhoni Banned, N. Srinivasan, Sreesanth suffering from Swine Flu, Sreesanth Swine Flu, Swine Flu in Indian Cricket Team, Swine Flu in Team India, Virender Sehwag, Virender Sehwag to Captain

Seven Brides for Seven Brothers | 7 Brides for 7 Brothers | Seven Brides for Seven Brothers Cast | Seven Brides for Seven Brothers Musical Film | Seven Brides for Seven Brothers Stanley Donen | Seven Brides for Seven Brothers Albert Hackett

Seven Brides for Seven Brothers is a musical film released in 1954. It was directed by Stanley Donen, with music by Saul Chaplin and Gene de Paul, and lyrics by Johnny Mercer. The script by Albert Hackett, Frances Goodrich, and Dorothy Kingsley is based on the short story The Sobbin’ Women, by Stephen Vincent Benét, which was based in turn on the Ancient Roman legend of The Rape of the Sabine Women. The film was a 1954 Oscar nominee for Best Picture.

The film is particularly known for the unusual choreography by Michael Kidd, which makes dance numbers out of such mundane frontier pursuits as chopping wood and most famously raising a barn.

In his introduction to a showing of the film on TCM January 17, 2009, Robert Osborne says MGM was much less interested in the film than it was in Brigadoon which was also in production at the time, even cutting its budget and transferring the money to the Lerner and Lowe vehicle.

On the 2004 DVD commentary, Stanley Donen states that the film was originally shot in two versions, one widescreen and another in normal ratio, because MGM was concerned that not all theaters had the capability to screen it. Despite the fact that it cost more than the widescreen version to make, he says, the other version was never used. However both versions are available on the 2004 DVD release.(Wiki)

Karthik replaces Dhoni, Ishant recalled for next two ODIs | Virender Sehwag to lead India in next two ODIs | MS DHoni Banned for 2 ODI’s | Mahendra S Dhoni Banned | M. S Dhoni Banned | Dhoni Banned | Dhoni banned for 2 ODI’s for slow over rate | Jeff Crowe

Karthik replaces Dhoni, Ishant recalled for next two ODIs | Virender Sehwag to lead India in next two ODIs | MS DHoni Banned for 2 ODI’s | Mahendra S Dhoni Banned | M. S Dhoni Banned | Dhoni Banned | Dhoni banned for 2 ODI’s for slow over rate | Jeff Crowe

Indian captain Mahendra S Dhoni has been banned for two ODI’s for the team’s slow over-rate during the 2nd ODI against Sri Lanka in Nagpur on Friday, 18th December 2009.

The nail biting 2nd ODI took 45 more minutes after the scheduled finish time due to the frequent discussions among the Indian players and the Captain during the closing stages of the match, prompting the ICC to ban Dhoni.

The decision was taken by match referee Jeff Crowe, considering the huge extra time the Indians players took to finish their 50 overs.

In the absence of Dhoni, Sehwag will lead Team India in Cuttack and Kolkata. A

The 3rd ODI will be held in Cuttack on 21st December 2009, while the fourth ODI will be held in Kolkata on 24th December 2009.

Meanwhile, the selectors have recalled Dinesh Karthik to replace MS Dhoni. Pace bowler Ishant Sharma will replace S Sreesanth, who is recovering from Swine Flu.

Had flu? You may have H1N1 protection

People who have had repeated flu infections — or repeated flu vaccines — may have some protection against the new pandemic swine influenza, U.S. researchers said on Monday.

They found evidence that the human immune system can recognize bits of the new H1N1 virus that are similar to older, distantly related H1N1 strains.

“What we have found is that the swine flu has similarities to the seasonal flu, which appear to provide some level of pre-existing immunity. This suggests that it could make the disease less severe in the general population than originally feared,” said Alessandro Sette, director of the Center for Infectious Disease at California’s La Jolla Institute.

The study, published in the Proceedings of the National Academy of Sciences, may also help explain why many older people are less likely to have severe disease, said Allison Deckhut-Augustine of the National Institute of Allergy and Infectious Diseases.

“Adults may have some pre-existing immunity for H1N1,” Deckhut-Augustine said in a telephone interview.

That does not mean older people are protected from infection, and Deckhut-Augustine stressed that people should still be vaccinated against H1N1.

Swine flu has infected millions of people globally and killed an estimated 3,900 in the United States alone, according to the U.S. Centers for Disease Control and Prevention. Drug makers are struggling to make vaccines and governments are working to vaccinate their populations.

Bjoern Peters and colleagues at the La Jolla Institute looked at flu epitopes — molecular markers or structures that the immune system recognizes — dating back 20 years.

“We found that the immune system’s T-cells can recognize a significant percent of the markers in swine flu,” Peters said in a statement.

DUAL PROTECTION

The human immune system has two kinds of protection. Antibody response can prevent infection, while T-cells fight infection once it has occurred.

Peters and colleagues found T-cell protection but not antibody response.

“This T-cell response decreases severity of disease but doesn’t prevent infection,” said Deckhut-Augustine, whose agency helped pay for the study and maintains the public database that Peters used.

The effect could be cumulative, Peters said, which could explain why people over 50 seem to be less likely to get noticeable H1N1 infections.

“This may also suggest why children are more susceptible to severe infection and why they might need two boosts,” Deckhut-Augustine said. “They haven’t been around as long and they haven’t been exposed to different strains of H1N1 as long as adults.”

Influenza is a very mutation-prone virus and from year to year the circulating strains drift, or change slightly. This is why new vaccines must be formulated each year and why people can catch flu again and again.

The new H1N1 was a never-before-seen combination of swine flu viruses, with a sprinkling of human and avian flu virus genetic sequences. But its long-ago ancestor was an H1N1 virus first seen in the 1918 influenza pandemic that killed upwards of 50 million people.

The researchers found that the new H1N1 swine flu shared 49 percent of its epitopes with older, seasonal H1N1 strains.

Using blood from healthy donors, they found that T-cells could recognize about 17 percent of these markers.

(Editing by Eric Beech)

New air filter system can destroy up to 99.9 per cent of bugs on aircraft

London, September 16 (ANI): British researchers have developed an air filter system that destroys up to 99.9 per cent of infectious viruses and bacteria as well as pollutants that can circulate in the confines of an aircraft, especially on long-haul flights.

According to a report in The Times, the machine has been developed by aerospace giant BAE Systems, in collaboration with Quest International, a small company based in Cheadle, South Manchester, UK.

The device, called AirManager, uses a controlled electric field to filter out and destroy any airborne particles or germs as they pass through an aircraft’s air conditioning system, emitting only clean, sterilized air.

After four years of development and tests, BAE says it has received its first orders from a major European airline and announced the technology is also being considered for use in NHS hospitals as a way to stop the spread of “superbugs” such as MRSA and Clostridium difficile.

The air on board a passenger jet must be pressurized in order for passengers to be able to breathe, but scientists and lobby groups have previously claimed that passengers can be exposed to toxins as a result of the “bleed air” system that is used to redirect air from the engines to the cabin and cockpit.

Air inside the cabin is then circulated and re-circulated up to 30 times an hour, far more than in conventional air conditioning systems, meaning that infectious viruses and bacteria can quickly spread.

Unlike conventional filters, which are designed to sieve out particles from the air as it passes through perforated barriers at high speed, David Hallam, an engineer and founder of Quest International, said that the AirManager used an “avalanche of electrons” emitted in a closed electric field to break down and destroy the atomic structure of any pollutants or germs.

“This works with swine flu, avian flu, norovirus, MRSA, even a modified form of anthrax,” Hallam said.

Hallam said that he originally designed the “close coupled field” in the late 1990s to rid nursing homes of biological odours caused by bacteria.

But, the filter was later found to have an effect in reducing the airborne transmission of bacteria such as MRSA (methicillin-resistant Staphylococcus aureus) and Clostridium difficile.

BAE Systems expressed interest in the technology four years ago for use on aircraft and the system was recently tested on the flight deck and cabin air systems of Boeing 757 and Avro RJ passenger jets by five European airlines, with successful results. (ANI)